Oragenics (NYSE:OGEN) shares are trading higher on Tuesday after the company announced the FDA broadly supports its pre-IND development program for its SARS-CoV-2 vaccine.
Oragenics is focused on becoming a leader in developing novel antibiotics against infectious disease and on developing effective treatments for oral mucositis. Oragenics involves developing its antibiotic product candidate, OG716 as well as other homolog antibiotic product candidates, researching LBPs, and have other product candidates, including SMaRT Replacement Therapy positioned for out-licensing or partnering.
Oragenics shares traded up 8.26% to 65 cents on Tuesday. The stock has a 52-week high of $2.09 and a 52-week low of 36 cents.